Log in with your email address username.


[Correspondence] Oseltamivir for influenza – Authors’ reply

In September, we replied to separate letters from Mark Jones and colleagues1 and Peter Doshi and colleagues,2 groups associated with the Cochrane reviews of oseltamivir.3 Their letters were mainly concerned with the substance of findings in our individual patient data meta-analysis of adult treatment studies of oseltamivir.4 Doshi and colleagues noted that the overall results were not strikingly different from “already public data”. This is not surprising, as we were all analysing the same randomised controlled trials, with the addition of one that was made available to us.